{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T23:37:30Z","timestamp":1777333050210,"version":"3.51.4"},"reference-count":89,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.eprac.2026.03.003","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T23:54:23Z","timestamp":1773273263000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Approach to the Care of Patients With Recurrent Differentiated Thyroid Cancer: A Focus on Papillary Thyroid Carcinoma"],"prefix":"10.1016","author":[{"given":"Alejandro","family":"Roman-Gonzalez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alvaro","family":"Sanabria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5630-0609","authenticated-orcid":false,"given":"Sarimar","family":"Agosto-Salgado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.eprac.2026.03.003_bib1","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1001\/jama.2023.26348","article-title":"Thyroid cancer: a review","volume":"331","author":"Boucai","year":"2024","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.eprac.2026.03.003_bib2","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"10.1016\/j.eprac.2026.03.003_bib4","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1089\/thy.2017.0102","article-title":"Updated American Joint Committee on Cancer\/Tumor-Node-Metastasis Staging System for differentiated and anaplastic thyroid cancer (Eighth edition): what changed and why?","volume":"27","author":"Tuttle","year":"2017","journal-title":"Thyroid"},{"issue":"3","key":"10.1016\/j.eprac.2026.03.003_bib5","doi-asserted-by":"crossref","DOI":"10.1111\/nhs.70199","article-title":"Treatment-related decision fatigue in patients with recurrent papillary thyroid cancer: a qualitative study","volume":"27","author":"Ding","year":"2025","journal-title":"Nurs Health Sci"},{"issue":"2","key":"10.1016\/j.eprac.2026.03.003_bib6","doi-asserted-by":"crossref","DOI":"10.1530\/EC-21-0506","article-title":"Fatigue and quality of life among thyroid cancer survivors without persistent or recurrent disease","volume":"11","author":"Maki","year":"2022","journal-title":"Endocr Connect"},{"issue":"2","key":"10.1016\/j.eprac.2026.03.003_bib7","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.ecl.2014.02.007","article-title":"Persistent posttreatment fatigue in thyroid cancer survivors: a scoping review","volume":"43","author":"Sawka","year":"2014","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"11","key":"10.1016\/j.eprac.2026.03.003_bib8","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1089\/thy.2024.0271","article-title":"The defini tion of recurrence of differentiated thyroid cancer: a systematic review of the literature","volume":"34","author":"van de Berg","year":"2024","journal-title":"Thyroid"},{"issue":"8","key":"10.1016\/j.eprac.2026.03.003_bib9","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1177\/10507256251363120","article-title":"2025 American thyroid association management guidelines for adult patients with differentiated thyroid cancer","volume":"35","author":"Ringel","year":"2025","journal-title":"Thyroid"},{"issue":"5","key":"10.1016\/j.eprac.2026.03.003_bib10","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/cen.13378","article-title":"Management and outcome of clinically evident neck recurrence in patients with papillary thyroid cancer","volume":"87","author":"Wang","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"10.1016\/j.eprac.2026.03.003_bib11","doi-asserted-by":"crossref","first-page":"e569","DOI":"10.1210\/clinem\/dgad571","article-title":"The frequency of differentiated thyroid cancer recurrence in 2302 patients with excellent response to primary therapy","volume":"109","author":"Pa\u0142yga","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.eprac.2026.03.003_bib12","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/wjs.12289","article-title":"Predictors of distant metastatic recurrence in intermediate-risk papillary thyroid carcinoma","volume":"49","author":"Onoda","year":"2025","journal-title":"World J Surg"},{"issue":"5","key":"10.1016\/j.eprac.2026.03.003_bib13","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1245\/s10434-011-1890-1","article-title":"Regional recurrence after lymphadenectomy for clinically evident lymph node metastases from papillary thyroid cancer: a cohort study","volume":"19","author":"Shah","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.eprac.2026.03.003_bib14","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1007\/s00268-012-1423-5","article-title":"Prognostic factors for recurrence of papillary thyroid carcinoma in the lymph nodes, lung, and bone: analysis of 5,768 patients with average 10-year follow-up","volume":"36","author":"Ito","year":"2012","journal-title":"World J Surg"},{"issue":"3","key":"10.1016\/j.eprac.2026.03.003_bib15","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00268-011-1391-1","article-title":"Lymph node recurrence in patients with N1b papillary thyroid carcinoma who underwent unilateral therapeutic modified radical neck dissection","volume":"36","author":"Ito","year":"2012","journal-title":"World J Surg"},{"issue":"12","key":"10.1016\/j.eprac.2026.03.003_bib16","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1210\/clinem\/dgae329","article-title":"Synergy of nodal factors in predicting recurrence after treatment of N1b papillary thyroid carcinoma","volume":"109","author":"Xian","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.eprac.2026.03.003_bib17","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1007\/s00595-005-3021-8","article-title":"Retrospective analysis of predictive factors for recurrence after curatively resected papillary thyroid carcinoma","volume":"35","author":"Tanaka","year":"2005","journal-title":"Surg Today"},{"issue":"1","key":"10.1016\/j.eprac.2026.03.003_bib18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1756-6614-4-9","article-title":"Factors determining the persistence or recurrence of well-differentiated thyroid cancer treated by thyroidectomy and\/or radioiodine in the Boston, Massachusetts area: a retrospective chart review","volume":"4","author":"Leung","year":"2011","journal-title":"Thyroid Res"},{"key":"10.1016\/j.eprac.2026.03.003_bib19","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/3534783","article-title":"Male gender is associated with lymph node metastasis but not with recurrence in Papillary thyroid carcinoma","volume":"2022","author":"Zhu","year":"2022","journal-title":"Int J Endocrinol"},{"issue":"2","key":"10.1016\/j.eprac.2026.03.003_bib20","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1007\/s00268-012-1835-2","article-title":"Multifocality, but not bilaterality, is a predictor of disease recurrence\/persistence of papillary thyroid carcinoma","volume":"37","author":"Kim","year":"2013","journal-title":"World J Surg"},{"key":"10.1016\/j.eprac.2026.03.003_bib21","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/819797","article-title":"Clinical significance and prognostic impact of subcutaneous or intrastrap muscular recurrence of papillary thyroid carcinoma","volume":"2012","author":"Ito","year":"2012","journal-title":"J Thyroid Res"},{"issue":"9","key":"10.1016\/j.eprac.2026.03.003_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2025.110208","article-title":"Impact of microscopic margin involvement on recurrence of papillary thyroid carcinoma","volume":"51","author":"Kwon","year":"2025","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"10.1016\/j.eprac.2026.03.003_bib23","first-page":"R29","article-title":"Persistent disease and recurrence in differentiated thyroid cancer patients with undetectable postoperative stimulated thyroglobulin level","volume":"18","author":"Nascimento","year":"2011","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"10.1016\/j.eprac.2026.03.003_bib24","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1097\/JS9.0000000000001945","article-title":"Restratification of intermediate risk factors on the recurrence of papillary thyroid carcinoma: a retrospective cohort study","volume":"111","author":"Chen","year":"2025","journal-title":"Int J Surg"},{"issue":"2","key":"10.1016\/j.eprac.2026.03.003_bib25","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1634\/theoncologist.2012-0240","article-title":"Lymph node ratio predicts recurrence in papillary thyroid cancer","volume":"18","author":"Schneider","year":"2013","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.eprac.2026.03.003_bib26","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1245\/s10434-013-3258-1","article-title":"Lymph node ratio of the central compartment is a significant predictor for locoregional recurrence after prophylactic central neck dissection in patients with thyroid papillary carcinoma","volume":"21","author":"Ryu","year":"2014","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.eprac.2026.03.003_bib27","doi-asserted-by":"crossref","DOI":"10.1530\/EC-23-0297","article-title":"The prognostic power of gene mutations in thyroid cancer","volume":"13","author":"Ahmadi","year":"2024","journal-title":"Endocr Connect"},{"issue":"2","key":"10.1016\/j.eprac.2026.03.003_bib28","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41574-023-00920-6","article-title":"Genomic alterations in thyroid cancer: biological and clinical insights","volume":"20","author":"Landa","year":"2024","journal-title":"Nat Rev Endocrinol"},{"issue":"14","key":"10.1016\/j.eprac.2026.03.003_bib29","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1158\/1078-0432.CCR-23-0278","article-title":"Additional oncogenic alterations in RAS-driven differentiated thyroid cancers associate with worse clinicopathologic outcomes","volume":"29","author":"Bikas","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eprac.2026.03.003_bib30","article-title":"InTERTwined: how","author":"Landa","year":"2023","journal-title":"Curr Opin Endocr Metab Res"},{"issue":"38","key":"10.1016\/j.eprac.2026.03.003_bib31","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000044540","article-title":"Prognostic significance of BRAF V600E and TERT promoter mutations in radioiodine resistance and recurrence of differentiated thyroid cancer","volume":"104","author":"Nhung","year":"2025","journal-title":"Medicine (Baltimore)"},{"issue":"25","key":"10.1016\/j.eprac.2026.03.003_bib32","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1200\/JCO.2014.55.5094","article-title":"BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence","volume":"32","author":"Xing","year":"2014","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.eprac.2026.03.003_bib33","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/cen.12999","article-title":"TERT promoter mutations are a major indicator of recurrence and death due to papillary thyroid carcinomas","volume":"85","author":"Bullock","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"10.1016\/j.eprac.2026.03.003_bib34","doi-asserted-by":"crossref","first-page":"942","DOI":"10.4143\/crt.2015.362","article-title":"TERT promoter mutations and tumor persistence\/recurrence in papillary thyroid cancer","volume":"48","author":"Myung","year":"2016","journal-title":"Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.eprac.2026.03.003_bib35","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13000-020-00962-8","article-title":"Genomic characterization of high-recurrence risk papillary thyroid carcinoma in a southern Chinese population","volume":"15","author":"Li","year":"2020","journal-title":"Diagn Pathol"},{"issue":"6","key":"10.1016\/j.eprac.2026.03.003_bib36","first-page":"3803","article-title":"MicroRNA-mRNA integrated analysis based on a case of well-differentiated thyroid cancer with both metastasis and metastatic recurrence","volume":"40","author":"Zhang","year":"2018","journal-title":"Oncol Rep"},{"issue":"2","key":"10.1016\/j.eprac.2026.03.003_bib37","doi-asserted-by":"crossref","first-page":"183","DOI":"10.21053\/ceo.2021.02215","article-title":"Transcriptomic analysis of papillary thyroid cancer: a focus on immune-subtyping, oncogenic fusion, and recurrence","volume":"15","author":"Park","year":"2022","journal-title":"Clin Exp Otorhinolaryngol"},{"issue":"1","key":"10.1016\/j.eprac.2026.03.003_bib38","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1038\/s41467-024-47581-1","article-title":"Integrated proteogenomic and metabolomic characterization of papillary thyroid cancer with different recurrence risks","volume":"15","author":"Qu","year":"2024","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.eprac.2026.03.003_bib39","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1210\/clinem\/dgac009","article-title":"Circulating MicroRNA profiles as potential biomarkers for differentiated thyroid cancer recurrence","volume":"107","author":"Jankovic Miljus","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.eprac.2026.03.003_bib40","doi-asserted-by":"crossref","DOI":"10.1002\/gcc.23256","article-title":"Gene expression profiles of AHNAK2, DCSTAMP, FN1, and TERT correlate with mutational status and recurrence in papillary thyroid carcinoma","volume":"63","author":"Staubitz-Vernazza","year":"2024","journal-title":"Genes Chromosomes Cancer"},{"issue":"10","key":"10.1016\/j.eprac.2026.03.003_bib41","first-page":"1178","article-title":"Active surveillance of small metastatic lymph nodes as an alternative to surgery in selected patients with low-risk papillary thyroid cancer: a retrospective cohort study","volume":"32","author":"Jerkovich","year":"2022","journal-title":"Thyroid"},{"issue":"3","key":"10.1016\/j.eprac.2026.03.003_bib42","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1089\/thy.2022.0542","article-title":"Active surveillance of differentiated thyroid cancer metastatic cervical lymph nodes: a retrospective single-center cohort study","volume":"33","author":"Walter","year":"2023","journal-title":"Thyroid"},{"issue":"6","key":"10.1016\/j.eprac.2026.03.003_bib43","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1089\/thy.2012.0307","article-title":"The results of selective use of radioactive iodine on survival and on recurrence in the management of papillary thyroid cancer, based on memorial sloan-kettering cancer center risk group stratification","volume":"23","author":"Nixon","year":"2013","journal-title":"Thyroid"},{"key":"10.1016\/j.eprac.2026.03.003_bib44","article-title":"Outcomes of nonsuspicious contralateral nodules with active surveillance after lobectomy in patients with papillary thyroid carcinoma","volume":"13","author":"Huang","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"8","key":"10.1016\/j.eprac.2026.03.003_bib45","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1089\/thy.2011.0011","article-title":"Ultrasonographically detected small thyroid bed nodules identified after total thyroidectomy for differentiated thyroid cancer seldom show clinically significant structural progression","volume":"21","author":"Rondeau","year":"2011","journal-title":"Thyroid"},{"issue":"1","key":"10.1016\/j.eprac.2026.03.003_bib46","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3348\/kjr.2024.0963","article-title":"Radiofrequency ablation for recurrent thyroid cancers: 2025 Korean society of thyroid Radiology Guideline","volume":"26","author":"Ha","year":"2025","journal-title":"Korean J Radiol"},{"issue":"12","key":"10.1016\/j.eprac.2026.03.003_bib47","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/j.jvir.2024.08.008","article-title":"Role of locoregional therapies in the treatment of thyroid pathology: Proceedings from the Society of Interventional Radiology Foundation Research Consensus Panel","volume":"35","author":"Lam","year":"2024","journal-title":"J Vasc Interv Radiol"},{"issue":"4","key":"10.1016\/j.eprac.2026.03.003_bib48","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.jamcollsurg.2012.06.006","article-title":"Successful localization of recurrent thyroid cancer in reoperative neck surgery using ultrasound-guided methylene blue dye injection","volume":"215","author":"Harari","year":"2012","journal-title":"J Am Coll Surg"},{"issue":"2","key":"10.1016\/j.eprac.2026.03.003_bib49","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/coa.14126","article-title":"Reliability of radioguided occult lesion localization in reoperation of loco-regional persistent\/recurrent differentiated thyroid cancer: retrospective cohort study","volume":"49","author":"Cadena-Pi\u00f1eros","year":"2024","journal-title":"Clin Otolaryngol"},{"key":"10.1016\/j.eprac.2026.03.003_bib50","doi-asserted-by":"crossref","DOI":"10.20945\/2359-4292-2023-0146","article-title":"Active surveillance is a feasible and safe strategy in selected patients with papillary thyroid cancer and suspicious cervical lymph nodes detected after thyroidectomy","volume":"68","author":"Sol\u00f3rzano","year":"2024","journal-title":"Arch Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.eprac.2026.03.003_bib51","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1089\/thy.2009.0159","article-title":"Consensus statement on the terminology and classification of central neck dissection for thyroid cancer","volume":"19","author":"Carty","year":"2009","journal-title":"Thyroid"},{"issue":"6","key":"10.1016\/j.eprac.2026.03.003_bib52","doi-asserted-by":"crossref","first-page":"817","DOI":"10.3348\/kjr.2014.15.6.817","article-title":"Radiofrequency ablation to treat loco-regional recurrence of well-differentiated thyroid carcinoma","volume":"15","author":"Lee","year":"2014","journal-title":"Korean J Radiol"},{"key":"10.1016\/j.eprac.2026.03.003_bib53","doi-asserted-by":"crossref","DOI":"10.1089\/thy.2024.0090","article-title":"Neoadjuvant treatment of locally advanced thyroid cancer: a preliminary Latin American experience","author":"Pitoia","year":"2024","journal-title":"Thyroid"},{"issue":"4","key":"10.1016\/j.eprac.2026.03.003_bib54","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-24-0185","article-title":"Transforming thyroid cancer management: the impact of neoadjuvant therapy","volume":"32","author":"Califano","year":"2025","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.eprac.2026.03.003_bib55","doi-asserted-by":"crossref","DOI":"10.1002\/hed.27735","article-title":"Neoadjuvant therapy to improve resectability of advanced thyroid cancer: a real-world experience","author":"Russell","year":"2024","journal-title":"Head Neck"},{"issue":"6","key":"10.1016\/j.eprac.2026.03.003_bib56","first-page":"633","article-title":"Long-term results of external beam radiation therapy with or without concurrent chemotherapy in differentiated thyroid cancer","volume":"35","author":"Choi","year":"2025","journal-title":"Thyroid"},{"issue":"3","key":"10.1016\/j.eprac.2026.03.003_bib57","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.otohns.2009.12.034","article-title":"Stereotactic body radiotherapy for refractory cervical lymph node recurrence of nonanaplastic thyroid cancer","volume":"142","author":"Kim","year":"2010","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"9","key":"10.1016\/j.eprac.2026.03.003_bib58","doi-asserted-by":"crossref","first-page":"6752","DOI":"10.1245\/s10434-025-17434-2","article-title":"Adjuvant external beam radiotherapy reduces local recurrence in poorly differentiated thyroid cancer: a multicenter retrospective cohort study describing outcomes in the treatment of resectable poorly differentiated thyroid cancer","volume":"32","author":"Jonker","year":"2025","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.eprac.2026.03.003_bib59","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/jjco\/hyae158","article-title":"The role of external-beam radiotherapy for differentiated thyroid cancer","volume":"55","author":"Kawamoto","year":"2025","journal-title":"Jpn J Clin Oncol"},{"issue":"6","key":"10.1016\/j.eprac.2026.03.003_bib60","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1002\/hed.28076","article-title":"Toxicity and quality of life after locoregional radiotherapy in patients with thyroid cancer","volume":"47","author":"van den End","year":"2025","journal-title":"Head Neck"},{"issue":"3","key":"10.1016\/j.eprac.2026.03.003_bib61","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s11845-023-03559-4","article-title":"Tracheoesophageal fistula development following radiotherapy and tyrosine kinase inhibitors in a patient with advanced follicular thyroid carcinoma: a case-based review","volume":"193","author":"S Temperley","year":"2024","journal-title":"Ir J Med Sci"},{"issue":"5","key":"10.1016\/j.eprac.2026.03.003_bib62","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1089\/thy.2012.0598","article-title":"Aerodigestive fistula formation as a rare side effect of antiangiogenic tyrosine kinase inhibitor therapy for thyroid cancer","volume":"24","author":"Blevins","year":"2014","journal-title":"Thyroid"},{"issue":"4","key":"10.1016\/j.eprac.2026.03.003_bib63","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.suc.2024.02.005","article-title":"Management of poorly differentiated thyroid cancer and differentiated high-grade thyroid carcinoma","volume":"104","author":"Alam","year":"2024","journal-title":"Surg Clin North Am"},{"issue":"7","key":"10.1016\/j.eprac.2026.03.003_bib64","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1089\/thy.2023.0709","article-title":"Survival prognostication in patients with differentiated thyroid cancer and distant metastases: a SEER population-based study","volume":"34","author":"Chen","year":"2024","journal-title":"Thyroid"},{"issue":"10","key":"10.1016\/j.eprac.2026.03.003_bib65","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1089\/thy.2024.0240","article-title":"Brain metastases in differentiated thyroid cancer: clinical presentation, diagnosis, and management","volume":"34","author":"Prinzi","year":"2024","journal-title":"Thyroid"},{"key":"10.1016\/j.eprac.2026.03.003_bib66","article-title":"Liver metastases in thyroid cancer: epidemiology, risk stratification and survival outcomes in the immunotherapy era","volume":"16","author":"Xu","year":"2025","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.eprac.2026.03.003_bib67","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0238207","article-title":"Unusual metastases from differentiated thyroid cancers: a multicenter study in Korea","volume":"15","author":"Yoon","year":"2020","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.eprac.2026.03.003_bib68","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1177\/10507256251363120","article-title":"2025 American Thyroid Association Management Guidelines for adult patients with differentiated thyroid cancer","volume":"35","author":"Ringel","year":"2025","journal-title":"Thyroid\u00ae"},{"issue":"24","key":"10.1016\/j.eprac.2026.03.003_bib69","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000033878","article-title":"Clinical role of 18F-FDG PET\/CT for detection of radioactive iodine refractory differentiated thyroid cancer","volume":"102","author":"Tang","year":"2023","journal-title":"Medicine (Baltimore)"},{"issue":"8","key":"10.1016\/j.eprac.2026.03.003_bib70","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.3390\/diagnostics11081430","article-title":"Impact of 18F-FDG PET\/CT on clinical management of suspected radio-iodine refractory differentiated thyroid cancer (RAI-R-DTC)","volume":"11","author":"Lodi Rizzini","year":"2021","journal-title":"Diagnostics (Basel)"},{"issue":"1","key":"10.1016\/j.eprac.2026.03.003_bib71","doi-asserted-by":"crossref","DOI":"10.6004\/jnccn.2024.7072","article-title":"Definitive radiotherapy for oligometastatic and oligoprogressive thyroid cancer: a potential strategy for systemic therapy deferral","volume":"23","author":"Dudzinski","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"8","key":"10.1016\/j.eprac.2026.03.003_bib72","article-title":"Paraneoplastic diarrhea from medullary thyroid carcinoma resolved with Yttrium-90 radioembolization of liver metastases","volume":"2","author":"Hamidi","year":"2024","journal-title":"JCEM Case Rep"},{"issue":"7","key":"10.1016\/j.eprac.2026.03.003_bib73","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.jvir.2022.03.016","article-title":"Safety and efficacy of percutaneous cryoablation of extraspinal thyroid cancer bone metastases with curative intent: single-center experience with a median Follow-up of more than 5 years","volume":"33","author":"Autrusseau","year":"2022","journal-title":"J Vasc Interv Radiol"},{"issue":"12","key":"10.1016\/j.eprac.2026.03.003_bib74","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1245\/s10434-015-4497-0","article-title":"Prospective evaluation of zoledronic acid in the treatment of bone metastases from differentiated thyroid carcinoma","volume":"22","author":"Orita","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.eprac.2026.03.003_bib75","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3390\/cancers17030388","article-title":"Denosumab vs. zoledronic acid for metastatic bone disease: a comprehensive systematic review and meta-analysis of randomized controlled trials","volume":"17","author":"Wajda","year":"2025","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.eprac.2026.03.003_bib76","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1002\/hed.27025","article-title":"American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology group consensus statement on mutational testing in thyroid cancer: defining advanced thyroid cancer and its targeted treatment","volume":"44","author":"Shonka","year":"2022","journal-title":"Head Neck"},{"issue":"7","key":"10.1016\/j.eprac.2026.03.003_bib77","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med"},{"issue":"9940","key":"10.1016\/j.eprac.2026.03.003_bib78","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.eprac.2026.03.003_bib79","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S1470-2045(21)00332-6","article-title":"Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"22","author":"Brose","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.eprac.2026.03.003_bib80","first-page":"1184","article-title":"Dabrafenib versus dabrafenib + trametinib in BRAF-mutated radioactive iodine refractory differentiated thyroid cancer: results of a randomized, phase 2, open-label multicenter trial","volume":"32","author":"Busaidy","year":"2022","journal-title":"Thyroid"},{"issue":"9","key":"10.1016\/j.eprac.2026.03.003_bib81","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa2005651","article-title":"Efficacy of selpercatinib in RET-altered thyroid cancers","volume":"383","author":"Wirth","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.eprac.2026.03.003_bib82","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S2213-8587(21)00120-0","article-title":"Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1\/2 study","volume":"9","author":"Subbiah","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.eprac.2026.03.003_bib83","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1530\/EJE-21-1259","article-title":"Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma","volume":"186","author":"Waguespack","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.eprac.2026.03.003_bib84","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1009076","article-title":"Remarkable response to alectinib for metastatic papillary thyroid cancer with STRN-ALK fusion: a case report","volume":"12","author":"Zhu","year":"2022","journal-title":"Front Oncol"},{"issue":"8","key":"10.1016\/j.eprac.2026.03.003_bib85","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvaf098","article-title":"Redifferentiation effect of larotrectinib for NTRK fusion-positive pediatric thyroid cancer and outcomes after therapy","volume":"9","author":"Castellanos","year":"2025","journal-title":"J Endocr Soc"},{"issue":"5","key":"10.1016\/j.eprac.2026.03.003_bib86","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1158\/1078-0432.CCR-14-2915","article-title":"Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib","volume":"21","author":"Rothenberg","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.eprac.2026.03.003_bib87","doi-asserted-by":"crossref","first-page":"T179","DOI":"10.1530\/ERC-21-0024","article-title":"Redifferentiation-facilitated radioiodine therapy in thyroid cancer","volume":"28","author":"Lamartina","year":"2021","journal-title":"Endocrine-Related Cancer"},{"issue":"6","key":"10.1016\/j.eprac.2026.03.003_bib88","article-title":"Durable response to redifferentiation in a patient with metastatic NCOA4::RET fusion-driven papillary thyroid cancer","volume":"3","author":"Tarasova","year":"2025","journal-title":"JCEM Case Rep"},{"issue":"10","key":"10.1016\/j.eprac.2026.03.003_bib89","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1089\/thy.2023.0136","article-title":"Return of vocal fold motion and surgical preservation of invaded recurrent laryngeal nerves after the use of neoadjuvant therapy in patients presenting with advanced thyroid cancer and vocal fold paralysis: the lazarus effect","volume":"33","author":"Silver Karcioglu","year":"2023","journal-title":"Thyroid"},{"issue":"1","key":"10.1016\/j.eprac.2026.03.003_bib90","doi-asserted-by":"crossref","first-page":"E7","DOI":"10.1002\/hed.26527","article-title":"Neoadjuvant selpercatinib for advanced medullary thyroid cancer","volume":"43","author":"Jozaghi","year":"2021","journal-title":"Head Neck"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26008098?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26008098?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T22:59:23Z","timestamp":1777330763000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X26008098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":89,"alternative-id":["S1530891X26008098"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2026.03.003","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Approach to the Care of Patients With Recurrent Differentiated Thyroid Cancer: A Focus on Papillary Thyroid Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2026.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 AACE. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}